Study Finds Nutritional Deficiencies in Nearly 1 in 6 Children on GLP-1 Medications
A study conducted by researchers at Ann & Robert H. Lurie Children's Hospital of Chicago has found that 16.8% of pediatric patients aged 10 to 17 developed a nutritional deficiency within 12 months of starting GLP-1 receptor agonist therapy. This study, published on September 23, 2026, in the journal Childhood Obesity, specifically identified vitamin D deficiency as the most prevalent issue, affecting 12.4% of the children within the year following treatment initiation.
Senior author Justin Ryder, PhD, who serves as Vice Chair of Research for the Department of Surgery at Lurie Children's Hospital and is also an Associate Professor of Surgery and Pediatrics at Northwestern University Feinberg School of Medicine, emphasized the importance of understanding the risks associated with the pediatric use of GLP-1 medications during critical periods of growth and development. Nutritional deficiencies during adolescence can have lasting implications for skeletal health and overall development, making nutrients like vitamin D, iron, and calcium particularly crucial.
The researchers analyzed national administrative claims data from 2017 to 2022, covering over 100 million patients. They identified 2,031 GLP-1 users aged 10 to 17 who met continuous enrollment criteria and had no prior nutritional deficiency diagnoses. The study revealed that liraglutide, marketed under the brand names Victoza and Saxenda, accounted for 78.6% of prescriptions among the study population, while dulaglutide (Trulicity) and semaglutide (Ozempic and Wegovy) accounted for 10.4% and 9.1%, respectively.
Adolescence is a time of significant nutritional needs due to bone growth and other biological changes. The study's findings raise concerns about the potential impact of GLP-1 medications on appetite and food intake, underscoring the need for careful attention to nutrition in younger patients receiving these treatments.
Ryder noted that the study found only 5% of patients received nutritional counseling within 30 days of starting GLP-1 treatment, and less than 25% received such counseling within six months. This lack of nutritional support highlights a critical gap in care, suggesting that nutritional management should begin concurrently with GLP-1 therapy rather than waiting for deficiencies to emerge.
The study's results add to a growing body of research examining the effects of GLP-1 medications in pediatric populations. A separate report indicated that prescriptions for GLP-1 weight-loss drugs among children under 12 in the United States have surged more than 300-fold since 2019. Critics of the pharmaceutical industry have raised concerns about the long-term health effects of these medications on children.
In light of these findings, the researchers advocate for proactive nutritional management when GLP-1 medications are prescribed to children, emphasizing that nutritional support should be an integral part of treatment from the outset.




